BUENOS AIRES (Reuters) - Argentines living with HIV/AIDS and medics say spending cuts under libertarian President Javier ...

Argentina's HIV/AIDS treatment programs are facing cuts under President Milei's austerity measures, reducing budgets by 67% ...

Argentinian President Javier Milei has raised concerns for the HIV/AIDS patients and medics with his fiscal deficit ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...

Sunlenca's biannual shot could revolutionize HIV prevention, but access remains a key barrier, particularly in Latin America.

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot ...

Lenacapavir, an injectable PrEP taken twice a year, demonstrated 96% efficacy in preventing HIV infections in a global Phase ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...

Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more ...

David Oscar Harvey’s film, “Red Reminds Me…” is part of a Nov. 30 program being hosted by the Institute of Contemporary Art ...

The drugmaker said it is also working on establishing “fast, efficient pathways to reach all people who need or want ...